Traumatic Brain Injury (TBI)
Traumatic brain injury is one of the more misunderstood corners of psychedelic research, because almost none of it is actually about repairing the brain. The work that matters here targets the psychiatric and functional after-effects of TBI, the depression, anxiety, post-traumatic stress and disrupted functioning that often follow, especially in veterans exposed to blasts. The standout result is a striking but uncontrolled study of magnesium-ibogaine in 30 special-operations veterans, who reported large improvements in those symptoms. It is genuinely interesting and genuinely preliminary: observational, self-selected, conducted abroad, and using a drug that can stop the heart. Beyond it, the evidence is mostly animal studies and early observations, and ketamine’s main role in TBI is a separate, intensive-care one.
How are psychedelics being studied for traumatic brain injury? Traumatic brain injury results from an external force harming the brain, and its lasting effects can include cognitive, mood and behavioural difficulties. Psychedelic research here is at a very early, mostly preclinical stage, exploring whether compounds such as psilocybin might support brain plasticity and recovery, alongside interest in treating the depression and post-traumatic stress that often follow injury. There are few human trials, and questions about safety after brain injury are important. The evidence should be read as early and exploratory rather than established. Blossom tracks the trials and papers behind traumatic brain injury research so you can follow the evidence.
Data updated
Key Insights
- 1
The key distinction: this research is mostly about the psychiatric and functional after-effects of TBI (depression, anxiety, post-traumatic stress, persistent post-concussive symptoms), not about healing the structural brain injury. No psychedelic has been shown to repair brain damage.
- 2
The headline study is a 2024 report on 30 special-operations veterans with blast-related TBI who received magnesium-ibogaine at a clinic in Mexico, and reported large improvements in PTSD, depression, anxiety and functioning. It is the most striking signal in the field, and it is observational, self-selected and uncontrolled.
- 3
Ibogaine carries a real risk of fatal heart-rhythm disturbance, which is why magnesium is given alongside it to protect the heart. That danger, plus the unregulated, overseas setting in which much of this happens, is central to reading the results honestly.
- 4
Beyond ibogaine, the evidence thins fast. Psilocybin and related drugs show promise in animal models (neuroplasticity, reduced inflammation) and in early observational veteran retreats, but there is no controlled human trial showing they treat TBI or its after-effects.
- 5
Ketamine appears often in TBI research, but mostly in a separate role: as an anaesthetic and intensive-care drug for managing acute, severe brain injury, not as a psychedelic therapy. No psychedelic is approved for TBI or its sequelae.
By the numbers
- 12
- Trials tracked
- 13
- Papers tracked
- 1,015
- Trial participants
as of June 2026
as of June 2026
as of June 2026
What is Traumatic Brain Injury (TBI)?
Traumatic brain injury (TBI) is damage to the brain caused by an external force, from a fall, crash, assault or blast, ranging from mild concussion to severe, life-changing injury. It is extremely common: an estimated 70 million people sustain a TBI each year, and it is a leading cause of long-term disability[1]. Beyond the initial injury, many people are left with lasting problems, and it is those, rather than the structural damage itself, that psychedelic research is mostly trying to address.
That distinction is the most important thing to understand on this page. TBI frequently leaves people with depression, anxiety, post-traumatic stress, sleep problems, irritability and persistent post-concussive symptoms, a cluster that overlaps heavily with the conditions psychedelics are studied for elsewhere. So when a study reports that a psychedelic "helped TBI", it almost always means it helped these after-effects, not that it healed the brain. Keeping those two ideas separate is essential to reading the evidence without being misled.
This is also a field defined by a specific population. Much of the interest comes from military veterans, particularly those exposed to repeated blasts, who often carry a tangled combination of TBI, post-traumatic stress and other injuries that conventional treatments serve poorly. That overlap means this page sits close to our veterans and neurocognitive disorders pages, and shares their cautions.
Current Treatments
There is no medication that reverses traumatic brain injury. Acute care focuses on preventing further damage (managing pressure inside the skull, oxygen and blood flow), and recovery relies heavily on rehabilitation: physical, occupational, cognitive and speech therapy, adapted over months or years. For the psychiatric after-effects, the standard tools are the usual ones, antidepressants, talking therapies and trauma-focused treatments, alongside management of headache, sleep and pain.
The gap is real and specific. The mental-health and functional consequences of TBI, especially the combination of post-traumatic stress and depression seen in blast-injured veterans, are often stubbornly resistant to those standard treatments, and there is little that helps the people who remain severely impaired despite good rehabilitation. That hard-to-treat group, not TBI in general, is what the psychedelic research is aimed at, and it is why even a flawed but dramatic result has drawn so much attention. What follows is investigational and, for the most part, not available outside research or unregulated overseas clinics.
This report summarises what Blossom’s database shows about psychedelics and traumatic brain injury, and the first thing to be clear about is what the question actually is. Almost none of this research is about repairing the brain. It is about whether psychedelics can ease the psychiatric and functional after-effects of TBI, the depression, anxiety, post-traumatic stress and disrupted functioning that often follow, especially in veterans exposed to blasts. With that framing, the picture is one striking but flawed human result, a lot of promising biology, and very little controlled evidence.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for TBI or its after-effects. One of the drugs central to this page, ibogaine, can cause fatal heart-rhythm disturbances, and much of the treatment described happens in unregulated overseas clinics; this is not a safe thing to arrange independently. Established care for TBI, rehabilitation plus evidence-based treatment of depression, post-traumatic stress and other symptoms, remains the foundation. If you or a veteran you know is struggling, please work with a clinical team rather than seeking out these treatments alone.
A word on scope and numbers. Blossom tracks only a small number of papers and trials under this topic, and many of them are mechanism reviews, animal studies, or trials of ketamine for acute critical care rather than psychedelic therapy for the after-effects. The genuinely on-topic human evidence is tiny, effectively one observational ibogaine cohort and a scatter of early observations. Read the counts as a young field, not an established one.
The distinction that changes everything: injury versus after-effects
The single most important idea on this page is the difference between treating the brain injury and treating its consequences. A traumatic brain injury is structural damage, and there is no evidence that any psychedelic repairs it. What TBI also produces, very often, is a cluster of psychiatric and functional problems: depression, anxiety, post-traumatic stress, irritability, sleep disturbance and persistent post-concussive symptoms. Those problems are real, disabling and frequently resistant to standard treatment, and they overlap closely with the conditions psychedelics are studied for elsewhere on this site. So the honest claim the research can support is narrow: psychedelics might help the after-effects of TBI in some people, not that they heal the injury.
This matters because the looser version, "psychedelics treat brain injury", is both more exciting and less true, and it is the version that tends to circulate. Keeping the narrower claim in view is what separates a fair reading of this field from a hopeful one.
The magnesium-ibogaine study: dramatic and uncontrolled
The result that put TBI on the map is a 2024 study of the Stanford magnesium-ibogaine (MISTIC) protocol in 30 male special-operations veterans with histories of repeated blast exposure and mild TBI[1]. Almost all had clinically severe psychiatric symptoms. After treatment, they showed significant improvements in overall functioning immediately, and in PTSD, depression and anxiety at one month, with no serious adverse events reported. For a population that had often run out of options, those are arresting numbers, and they are the reason this field has momentum.
They have to be read with the design in full view. This was a prospective observational study, not a randomised controlled trial. The participants self-selected: they independently chose and paid to fly to a clinic in Mexico for ibogaine, which is a group primed to expect and report benefit. There was no placebo or comparison arm, the cohort was small, entirely male, and drawn from an unusual population, and the main follow-up was just one month. Each of those features inflates the apparent effect. There are also exploratory follow-on analyses of the same cohort, including reports of increased cortical thickness and a younger estimated brain age[2], which are biologically intriguing but cannot carry weight on their own. The fair conclusion is that this is a strong signal worth taking seriously and an unproven one, exactly the situation that calls for a controlled trial.
And ibogaine is not a benign drug to build a movement around. It can cause dangerous, sometimes fatal, disturbances of the heart’s rhythm; the magnesium in the protocol is there specifically to reduce that risk, not because it adds to the benefit. Combined with the unregulated, overseas settings in which most ibogaine treatment happens, that makes the safety dimension inseparable from the efficacy story.
Psilocybin and the rest: strong mechanism, thin human data
Away from ibogaine, the evidence is earlier still. The laboratory rationale is genuinely appealing: classic psychedelics promote neuroplasticity and reduce neuroinflammation, both relevant after a brain injury, and reviews of psychedelics for acquired brain injury set out these mechanisms in detail[3]. The human data, though, are observational and small: veterans with a history of TBI who attended psilocybin retreats reported better mental health and showed normalised resting-state brain activity[4], which is encouraging but uncontrolled and self-selected in the same way as the ibogaine work.
The encouraging development is that this is beginning to move into proper trials, with a study of psilocybin-assisted therapy for persistent post-concussive symptoms now recruiting. That is the right next step. Until such trials report, the honest status of psilocybin and the other classic psychedelics in TBI is: mechanistically plausible, supported by animal work and by hopeful observations in veterans, and not yet shown in any controlled human study to help.
Ketamine: two different drugs in one
Ketamine deserves its own note because it appears in TBI research wearing two different hats. The older and far better-established role is in acute critical care: ketamine is a fast-acting anaesthetic that does not suppress breathing, and it is used in the emergency and intensive-care management of severe brain injury, where studies examine its effects on physiology such as intracranial pressure and outcomes[5]. That is mainstream neurocritical care and has nothing to do with psychedelic therapy.
The newer role, and the one that belongs alongside the rest of this page, uses ketamine’s rapid antidepressant and anti-suicidal effects to treat the depression and post-traumatic stress that follow TBI. Several trials are now testing this. It is a reasonable idea with a track record in depression generally, but in the specific context of TBI sequelae it is early and unproven. The key is simply not to confuse the two ketamines: the acute-care drug is well established; the psychiatric-sequelae treatment is a hypothesis in testing.
Reading this honestly
So where does TBI sit? It is a young, thin and unusually hype-prone field, carried by a real human need and one dramatic result. The truthful summary has several parts that must be held together: the meaningful target is the psychiatric and functional after-effects of TBI, not the injury itself; the standout magnesium-ibogaine finding is genuinely striking and genuinely uncontrolled, and rests on a drug that can be lethal; the rest of the evidence is animal models and hopeful observations; and ketamine’s main TBI role is a separate, intensive-care one. For people living with the after-effects of brain injury, and for the veterans who dominate this story, the honest message is that this is a promising, fast-moving area worth watching closely and a set of treatments that are not yet proven, not yet safe to pursue independently, and no substitute for the rehabilitation and evidence-based mental-health care that remain the foundation of recovery.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Traumatic Brain Injury (TBI).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Ibogaine The only compound with a real human TBI signal, and it is for the psychiatric after-effects, not the injury. A 2024 observational study of magnesium-ibogaine in 30 special-operations veterans reported large improvements in PTSD, depression, anxiety and functioning at one month. But it was uncontrolled, self-selected, all-male, conducted abroad, and ibogaine can cause fatal heart-rhythm disturbance (magnesium is added to mitigate this). Striking but unproven. | Medium | Low | Low |
| Psilocybin No controlled human evidence in TBI. Promise rests on animal models (neuroplasticity, reduced inflammation) and early observational data from veteran psilocybin retreats; a first trial for persistent post-concussive symptoms is recruiting. A plausible, mechanism-driven hypothesis, not yet a demonstrated treatment. | Small | Very Low | Low |
| Ketamine Mostly a different conversation: ketamine is an established anaesthetic and intensive-care drug used in acute, severe TBI (sedation, intracranial pressure), which is not psychedelic therapy. Its use for the psychiatric after-effects of TBI (depression, PTSD) is only beginning to be trialled. Useful in acute care; exploratory for the sequelae. | Small | Low | Low |
Ibogaine and Traumatic Brain Injury (TBI)
Ibogaine is the reason TBI is on the psychedelic map, through a single, much-discussed study. A 2024 report followed 30 male special-operations veterans with a history of repeated blast exposure and mild TBI, almost all with clinically severe psychiatric symptoms, who travelled to a clinic in Mexico for the Stanford magnesium-ibogaine (MISTIC) protocol, and found large improvements in functioning immediately and, at one month, in PTSD, depression and anxiety[1]. For a group that had often exhausted conventional options, the size of the reported change was remarkable.
The caveats are just as important as the result. It was an observational study with no control group, in people who had self-selected and self-funded an overseas treatment, all of them male special-operations veterans, with only a one-month primary follow-up, which is the textbook recipe for a strong placebo and expectancy effect. And ibogaine is genuinely dangerous: it can trigger fatal cardiac arrhythmia, which is why magnesium is co-administered to protect the heart. There are intriguing follow-on hints of brain-level change, including a report of increased cortical thickness and a lower estimated brain age in the same cohort[2], but these are exploratory analyses of one small, uncontrolled group. The honest reading is a dramatic, biologically interesting signal that urgently needs a controlled trial, given inside a serious safety warning.
Psilocybin and Traumatic Brain Injury (TBI)
Psilocybin’s case in TBI is mostly mechanistic and early. In the laboratory, classic psychedelics promote neuroplasticity and dampen inflammation, and reviews of psychedelics for acquired brain injury lay out why that biology is appealing after a brain injury[1]. In people, the data so far are observational: veterans with a history of TBI who attended psilocybin retreats reported improved mental health and showed normalised resting brain activity on EEG[2], which is suggestive but uncontrolled.
A first clinical trial of psilocybin-assisted therapy for persistent post-concussive symptoms is now recruiting, which is the kind of study the field needs. Until it and others report, psilocybin in TBI should be read as a well-motivated hypothesis, strong on mechanism and short on controlled human evidence, rather than an established treatment. As everywhere here, any benefit is most likely on the psychiatric after-effects rather than on the underlying injury.
Ketamine and Traumatic Brain Injury (TBI)
Ketamine appears throughout TBI research, but mostly in a role that has nothing to do with psychedelic therapy. As a fast-acting anaesthetic that does not depress breathing, it is used in the acute, intensive-care management of severe brain injury, where analyses of its use after TBI examine its effects on physiology such as intracranial pressure[1]. That is a mainstream critical-care question, separate from the rest of this page.
Its other, much newer role is the one that fits this site: using ketamine’s rapid antidepressant effect for the depression and post-traumatic stress that follow TBI. A handful of trials are now testing exactly that. But this is early, and it should not be confused with the established acute-care use. For the psychiatric after-effects of TBI, ketamine is a plausible, fast-acting candidate still awaiting proper evidence.
Clinical Outlook
The near-term outlook is a field waiting for its first real trials. The magnesium-ibogaine result has generated genuine momentum and a push toward controlled studies, a psilocybin trial for post-concussive symptoms is recruiting, and ketamine trials for TBI-related depression and PTSD are getting under way. Mechanistically the rationale is sound, and the broader literature on psychedelics for brain injury continues to argue that the neuroplasticity and anti-inflammatory effects are worth pursuing[1]. The missing ingredient is not enthusiasm but rigour.
The realistic outlook therefore holds promise and caution in tension. There is a real chance that psychedelics help with the disabling psychiatric after-effects of TBI, particularly in blast-injured veterans, and almost no good evidence yet that they do, nor that they repair the injury. Meanwhile a stream of early case reports and microdosing protocols for post-concussive and other brain injuries[2] keeps the hype ahead of the data, and the overseas, unregulated nature of much ibogaine treatment adds real risk. The most useful thing that could happen is the least glamorous: properly controlled trials in this group.
Industrial Landscape
The driving forces here are unusual. Much of the momentum comes from the veteran community and the researchers and philanthropists around it, motivated by the toll of blast injuries and post-traumatic stress and frustrated by the limits of conventional care. The Stanford group behind the magnesium-ibogaine study, veteran-led advocacy organisations, and a small number of overseas clinics together account for most of the activity, which gives the field energy and a strong sense of mission, but also a built-in optimism that has to be watched.
For an honest broker, TBI is a case where a compelling human story and a dramatic early result can easily outrun the evidence, and where the stakes of getting it wrong are high: ibogaine can kill, and the people seeking it are often desperate and unwell. The responsible posture is to take the veteran experience and the magnesium-ibogaine signal seriously enough to demand the controlled trials that would confirm or refute them, while being candid that, today, this is promising research and an unregulated overseas treatment, not an established therapy.
Quick Indicators
Related Topics
Organisations
Search →University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Columbia University
Research with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
Johns Hopkins University
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Stanford University
At the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).
AZ Delta
AZ Delta is a major Belgian hospital group headquartered in Roeselare, Flanders, operating four campuses with 1,403 approved beds. It participates in the multi-centre BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's safety as an adjunct sedative in severe traumatic brain injury.
AZ Sint-Jan AV
AZ Sint-Jan Brugge-Oostende AV is a leading Belgian teaching hospital in Bruges with a dedicated Clinical Trial Center (CTC) that sponsors and participates in academic and commercial drug studies. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine's role in severe traumatic brain injury management.
AZ Turnhout
AZ Turnhout is a general hospital in Turnhout, Antwerp province, Belgium, providing comprehensive medical and surgical care to the northern Campine region. Its Department of Anesthesiology and Intensive Care Medicine is a confirmed site in the BIKe (Brain Injury and Ketamine) randomized controlled trial (NCT05097261) investigating ketamine as an adjunct sedative in severe traumatic brain injury patients.
Brooke Army Medical Center
Brooke Army Medical Center (BAMC) at Joint Base San Antonio is the US Army's flagship medical institution and the Department of Defense's only Level I Trauma Center, and has been a primary site in multi-center randomized controlled trials investigating ketamine for antidepressant-resistant PTSD in active duty military and veterans. BAMC researchers have also contributed to pilot studies on service members' perspectives on psychedelic-assisted therapies including MDMA and psilocybin for PTSD and traumatic brain injury.
Centre Hospitalier Régional de la Citadelle
CHR de la Citadelle is a large public hospital in Liège, Belgium, whose Department of Anesthesia and Intensive Care participated in the first double-blind placebo-controlled feasibility trial of sub-anesthetic ketamine for prolonged disorders of consciousness, demonstrating increased brain complexity and reduced spastic paresis.
Copenhagen Trial Unit, Center for Clinical Intervention Research
The Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, is a non-specialty clinical research unit at Rigshospitalet (Copenhagen University Hospital), supporting rigorous randomised clinical trials and systematic reviews across all medical disciplines since 2000. Located at the same hospital campus as the Neurobiology Research Unit conducting active psilocybin neuroimaging studies, CTU provides the trial methodology, statistical expertise, and conduct infrastructure that enables clinical psychedelic research in Denmark.
Henry M. Jackson Foundation for the Advancement of Military Medicine
The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a congressionally chartered non-profit founded in 1983 that manages research contracts and grants for the U.S. Department of Defense across global health, HIV, TBI, and PTSD. HJF is affiliated with clinical research investigating ketamine for sedation in severe traumatic brain injury — a condition at the intersection of military medicine and emerging ketamine-based therapies.
Imelda Hospital, Bonheiden
Imelda Hospital is a Catholic general hospital in Bonheiden, in the Antwerp province of Belgium, offering a full range of acute care and specialist services across approximately 550 beds. The hospital has contributed to clinical research on ketamine for the management of acute brain injury patients.
People
Search →Jessica Maples-Keller
Associate Professor in the Emory School of Medicine, Department of Psychiatry and Behavioral Sciences; Associate Director of the Emory Healthcare Veterans Program
She is a prominent translational PTSD and psychedelic-therapy researcher contributing to MDMA and psilocybin studies, including work on fear extinction, treatment barriers, and culturally informed psychedelic-assisted therapy.
Alan Davis
Associate Professor of Social Work & Director, Center for Psychedelic Drug Research
Noted for advancing epidemiological, naturalistic and mixed-method research on therapeutic and adverse outcomes of psychedelics and for translating those findings into clinical and harm-reduction contexts.
Nathan Sepeda
Director of Data & Analytics
Notable for his contributions to clinical and experimental studies of psilocybin-assisted interventions, including trials of major depressive disorder and investigations of enduring psychological and neurofunctional effects.
Robin Carhart-Harris
Ralph Metzner Distinguished Professor
Pioneering researcher in brain imaging of psychedelics and founding director of the UCSF Neuroscape Psychedelics Division.
David Erritzoe
Clinical Associate Professor in Psychopharmacology
Head of the Centre for Psychedelic Research at Imperial College London and director of the CIPPRes Clinic.
Leor Roseman
Senior Lecturer and Psychedelic Researcher
Expert in the psychological and social impacts of psychedelics and their potential in conflict resolution.
Hannes Kettner
Research Specialist at UCSF and PhD Candidate at Imperial College London
A leading expert in the observational study of 'set and setting' and its influence on the psychedelic experience.
Matthew Johnson
Professor of Psychiatry
A leading clinical researcher who has advanced evidence on the therapeutic potential and safety of classic psychedelics—particularly psilocybin—for addiction and mental health outcomes through clinical trials, survey research and methodological guidance.
Lauren Averill
Researcher
Noted for clinical and translational research on psychedelic-assisted treatments for trauma-related disorders, particularly among military and veteran populations, and for contributions to ethical and implementation issues in psychedelic medicine.
Simon Ruffell
Psychiatrist and psychedelic researcher; Senior Research Associate at King's College London / affiliated with Onaya Science
He is notable for leading and coauthoring naturalistic and review studies on ayahuasca and psilocybin, including work on veterans, mental health outcomes, EEG, epigenetics, and the gut-brain axis.
Yitong Xin
Assistant Professor at the College of Social Work, University of Utah
Xin is notable for psychedelic and psychiatric research on trauma, substance use, and cultural/racial outcomes, including work on special operations veterans and people of color.
Martin Polanco
M.D.; Founder of The Mission Within and Clinic Founder/Psychedelic Researcher
He is notable for clinical and phenomenological research on ibogaine and 5-MeO-DMT, especially in addiction and veteran mental health contexts.
Connected Evidence
The latest clinical data and verified academic findings associated with Traumatic Brain Injury (TBI).